Back to News
Market Impact: 0.6

Zoetis Boosts FY25 Outlook As Q2 Results Top Estimates

ZTSNDAQ
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsAnalyst EstimatesHealthcare & Biotech
Zoetis Boosts FY25 Outlook As Q2 Results Top Estimates

Zoetis (ZTS) reported robust second-quarter results, with adjusted earnings of $1.76 per share and revenue of $2.46 billion, both surpassing analyst expectations, driven by 8% organic operational revenue growth. Following this performance, the animal health company raised its full-year 2024 guidance, now forecasting adjusted earnings of $6.30-$6.40 per share and revenues of $9.45-$9.60 billion. This upward revision, with the new adjusted EPS range exceeding the $6.21 analyst consensus, signals continued strong momentum and a positive outlook for the company.

Analysis

Zoetis (ZTS) reported a strong second quarter, exceeding analyst expectations on both top and bottom lines with revenues of $2.46 billion against a $2.41 billion estimate and adjusted earnings of $1.76 per share, surpassing the $1.61 consensus. The core driver of this outperformance was an 8% increase in organic operational revenue, which strips out unfavorable foreign exchange impacts and demonstrates robust underlying business momentum. Following this strong performance, the company raised its full-year 2024 guidance. The revised adjusted earnings forecast of $6.30 to $6.40 per share is particularly notable, as the entire range now sits above the Thomson Reuters analyst consensus of $6.21. The revenue guidance was also lifted to a range of $9.45 billion to $9.60 billion, which now firmly brackets the consensus estimate. This combination of a quarterly beat and a significant guidance raise signals strong operational execution and management confidence, even after accounting for stated assumptions on foreign exchange and tariffs.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo